Insider · CIK 0001754403

SCHMIDT ERIC THOMAS

Reports to the SEC for 3 companies · SOUTH SAN FRANCISCO, CA

sec.gov

Transactions

Companies

Filings

CIK

0001754403

Forms 4 and 5

Insider transactions

50 trades

Date	Company	Role	Code	Shares	Price	Value	Shares after
2023-06-08	RVMDRevolution Medicines, Inc.A Award	Director	AAward	+5,200 sh	—	—	21,251
2023-06-08	RVMDRevolution Medicines, Inc. · Stock Option (Right to Buy)A Award	Director	AAward	+18.4K sh	—	—	18,400
2023-05-25	RLMDRELMADA THERAPEUTICS, INC. · Stock Option (right to buy)A Award	Director	AAward	+93K sh	—	—	150,000
2023-03-22	ALLOAllogene Therapeutics, Inc.A Award	Chief Financial Officer	AAward	+558K sh	—	—	862,439
2023-03-22	ALLOAllogene Therapeutics, Inc. · Stock Option (Right to Buy)A Award	Chief Financial Officer	AAward	+433K sh	—	—	432,738
2023-03-14	ALLOAllogene Therapeutics, Inc.F Tax Payment	Chief Financial Officer	FTax Payment	−35.9K sh	$5.47	−$196K	304,345
2022-12-16	RLMDRELMADA THERAPEUTICS, INC. · Stock Option (right to buy)A Award	Director	AAward	+57K sh	—	—	57,042
2022-06-16	RVMDRevolution Medicines, Inc.A Award	Director	AAward	+5,200 sh	—	—	16,051
2022-06-16	RVMDRevolution Medicines, Inc. · Stock Option (Right to Buy)A Award	Director	AAward	+18.4K sh	—	—	18,400
2022-05-25	RLMDRELMADA THERAPEUTICS, INC. · Stock Option (right to buy)A Award	Director	AAward	+91.2K sh	—	—	150,000
2022-03-23	ALLOAllogene Therapeutics, Inc.A Award	Chief Financial Officer	AAward	+237K sh	—	—	337,904
2022-03-23	ALLOAllogene Therapeutics, Inc. · Stock Option (Right to Buy)A Award	Chief Financial Officer	AAward	+369K sh	—	—	368,589
2022-03-15	ALLOAllogene Therapeutics, Inc.S Sale	Chief Financial Officer	SSale	−11.5K sh	$7.63	−$87.6K	100,546
2021-12-17	RLMDRELMADA THERAPEUTICS, INC. · Stock Option (right to buy)A Award	Director	AAward	+58.8K sh	—	—	58,765
2021-06-22	RVMDRevolution Medicines, Inc.A Award	Director	AAward	+3,617 sh	—	—	10,851
2021-06-22	RVMDRevolution Medicines, Inc. · Stock Option (Right to Buy)A Award	Director	AAward	+12.7K sh	—	—	12,659
2021-05-24	ALLOAllogene Therapeutics, Inc.M Exercise/Conversion	Chief Financial Officer	MExercise/Conversion	+14.9K sh	$18.22	+$271K	110,994
2021-05-24	ALLOAllogene Therapeutics, Inc. · Stock Option (Right to Buy)M Exercise/Conversion	Chief Financial Officer	MExercise/Conversion	−14.9K sh	—	—	94,703
2021-03-26	ALLOAllogene Therapeutics, Inc.A Award	Chief Financial Officer	AAward	+24.9K sh	—	—	96,097
2021-03-26	ALLOAllogene Therapeutics, Inc. · Stock Option (Right to Buy)A Award	Chief Financial Officer	AAward	+92.4K sh	—	—	92,365
2021-03-15	ALLOAllogene Therapeutics, Inc.S Sale	Chief Financial Officer	SSale	−8,053 sh	$38.23	−$308K	71,231
2021-01-15	ALLOAllogene Therapeutics, Inc.S Sale	Chief Financial Officer	SSale	−3,547 sh	$31.69	−$112K	1,164,048
2021-01-15	ALLOAllogene Therapeutics, Inc.S Sale	Chief Financial Officer	SSale	−11.1K sh	$32.40	−$358K	1,152,995
2021-01-15	ALLOAllogene Therapeutics, Inc.S Sale	Chief Financial Officer	SSale	−400 sh	$33.28	−$13.3K	1,152,595
2021-01-14	ALLOAllogene Therapeutics, Inc.S Sale	Chief Financial Officer	SSale	−9,851 sh	$30.60	−$301K	1,172,744
2021-01-14	ALLOAllogene Therapeutics, Inc.S Sale	Chief Financial Officer	SSale	−5,149 sh	$31.10	−$160K	1,167,595
2021-01-07	RLMDRELMADA THERAPEUTICS, INC. · Options to purchase common stockA Award	Director	AAward	+100K sh	—	—	100,000
2020-11-16	ALLOAllogene Therapeutics, Inc.S Sale	Chief Financial Officer	SSale	−4,634 sh	$32.60	−$151K	1,192,961
2020-11-16	ALLOAllogene Therapeutics, Inc.S Sale	Chief Financial Officer	SSale	−10.4K sh	$33.00	−$342K	1,182,595
2020-10-15	ALLOAllogene Therapeutics, Inc.S Sale	Chief Financial Officer	SSale	−5,104 sh	$39.47	−$201K	1,207,491
2020-10-15	ALLOAllogene Therapeutics, Inc.S Sale	Chief Financial Officer	SSale	−4,218 sh	$40.07	−$169K	1,203,273
2020-10-15	ALLOAllogene Therapeutics, Inc.S Sale	Chief Financial Officer	SSale	−3,479 sh	$41.33	−$144K	1,199,794
2020-10-15	ALLOAllogene Therapeutics, Inc.S Sale	Chief Financial Officer	SSale	−2,099 sh	$42.32	−$88.8K	1,197,695
2020-10-15	ALLOAllogene Therapeutics, Inc.S Sale	Chief Financial Officer	SSale	−100 sh	$43.01	−$4,301	1,197,595
2020-09-21	ALLOAllogene Therapeutics, Inc.S Sale	Chief Financial Officer	SSale	−9,889 sh	$34.76	−$344K	1,217,706
2020-09-21	ALLOAllogene Therapeutics, Inc.S Sale	Chief Financial Officer	SSale	−3,200 sh	$35.96	−$115K	1,214,506
2020-09-21	ALLOAllogene Therapeutics, Inc.S Sale	Chief Financial Officer	SSale	−1,911 sh	$37.04	−$70.8K	1,212,595
2020-06-17	RVMDRevolution Medicines, Inc.A Award	Director	AAward	+7,234 sh	—	—	7,234
2020-06-17	RVMDRevolution Medicines, Inc. · Stock Option (Right to Buy)A Award	Director	AAward	+25.3K sh	—	—	25,318
2020-04-09	RLMDRELMADA THERAPEUTICS, INC.X Exercise of In-Money	Director	XExercise of In-Money	+32.5K sh	$6.00	+$195K	87,500
2020-04-09	RLMDRELMADA THERAPEUTICS, INC.X Exercise of In-Money	Director	XExercise of In-Money	+12.5K sh	$9.00	+$113K	100,000
2020-04-09	RLMDRELMADA THERAPEUTICS, INC. · Warrants to purchase common stockX Exercise of In-Money	Director	XExercise of In-Money	−32.5K sh	$6.00	−$195K	0
2020-04-09	RLMDRELMADA THERAPEUTICS, INC. · Warrants to purchase common stockX Exercise of In-Money	Director	XExercise of In-Money	−12.5K sh	$9.00	−$113K	0
2020-03-18	ALLOAllogene Therapeutics, Inc.A Award	Chief Financial Officer	AAward	+30.8K sh	—	—	78,706
2020-03-18	ALLOAllogene Therapeutics, Inc. · Stock Option (Right to Buy)A Award	Chief Financial Officer	AAward	+110K sh	—	—	109,600
2020-03-16	ALLOAllogene Therapeutics, Inc.S Sale	Chief Financial Officer	SSale	−5,150 sh	$19.70	−$101K	47,257
2020-03-16	ALLOAllogene Therapeutics, Inc.S Sale	Chief Financial Officer	SSale	−300 sh	$20.25	−$6,075	47,906
2020-02-20	ALLOAllogene Therapeutics, Inc.J Other	Chief Financial Officer	JOther	−237K sh	$25.30	−$6M	1,227,595
2019-03-13	ALLOAllogene Therapeutics, Inc.A Award	Chief Financial Officer	AAward	+49.4K sh	—	—	49,400
2019-03-13	ALLOAllogene Therapeutics, Inc. · Employee Stock Option (Right to Buy)A Award	Chief Financial Officer	AAward	+83.5K sh	—	—	83,500

Recent filings

Accepted (ET)
Jun 124
SCHMIDT ERIC THOMAS0001610717-23-000132
SEC(opens sec.gov)
May 304
SCHMIDT ERIC THOMAS0001213900-23-044088
SEC(opens sec.gov)
Mar 244
SCHMIDT ERIC THOMAS0001593968-23-000527
SEC(opens sec.gov)
Mar 164
SCHMIDT ERIC THOMAS0001737287-23-000024
SEC(opens sec.gov)
Dec 204
SCHMIDT ERIC THOMAS0001213900-22-081478
SEC(opens sec.gov)
Jun 174
SCHMIDT ERIC THOMAS0001567619-22-013110
SEC(opens sec.gov)
May 264
SCHMIDT ERIC THOMAS0001213900-22-029834
SEC(opens sec.gov)
Mar 254
SCHMIDT ERIC THOMAS0001214659-22-004371
SEC(opens sec.gov)
Mar 174
SCHMIDT ERIC THOMAS0001214659-22-004084
SEC(opens sec.gov)
Dec 214
SCHMIDT ERIC THOMAS0001213900-21-066823
SEC(opens sec.gov)
Jun 244
SCHMIDT ERIC THOMAS0001567619-21-012591
SEC(opens sec.gov)
May 264
SCHMIDT ERIC THOMAS0001214659-21-005926
SEC(opens sec.gov)
Mar 304
SCHMIDT ERIC THOMAS0001214659-21-003603
SEC(opens sec.gov)

Companies

Address

210 EAST GRAND AVENUE

SOUTH SAN FRANCISCO, CA, 94080